Chemotherapy impact on the gut microbiota.

Published: 21 April 2020| Version 1 | DOI: 10.17632/n4v5sj5fhz.1


Article Title: IMPACT OF PEMETREXED CHEMOTHERAPY ON THE GUT MICROBIOTA AND INTESTINAL INFLAMMATION OF PATIENT-LUNG-DERIVED TUMOUR XENOGRAFT (PDX) MOUSE MODELS Author names: Cindy Pensec, Florence Gillaizeau, Dominique Guenot, Anne Bessard, Thomas Carton, Sébastien Leuillet, Mario Campone, Michel Neunlist, Hervé M. Blottière and Françoise Le Vacon*. Chemotherapy remains the gold standard for advanced cancer. Pemetrexed, a chemotherapeutic agent used in non-small cell lung cancer, can induce significant side effects in patients. Although microbiota’s role in the efficacy and/or toxicity of chemotherapy agents has been demonstrated. The impacts of pemetrexed on the gut microbiota and on gastrointestinal inflammation remain unknown. The objective of this study was to evaluate the impact of pemetrexed and the tumour graft on the gut microbiota composition in immunodeficient mice. The faecal microbiota composition was studied with metabarcoding before, 24-h after and one week after treatment. All FastQ are present in this dataset. The tumour graft induced some variations in the faecal microbiota composition. Pemetrexed further increased the relative abundance of Enterobacteriaceae and 3 families from the Firmicutes phylum: Enterococcaceae, Lactobacillaceae and Streptococcaceae. This pilot study shows that the association of a lung tumour with the chemotherapeutic agent pemetrexed causes an alteration in the microbiota composition. Such information increases our knowledge about the impact of chemotherapy on the microbiota, which could help to minimize side effects and improve therapeutic effectiveness in the future.



Cancer, Microbiome, Lung Cancer